Shares of Alembic Prescribed drugs witnessed a constructive transfer, gaining 2%, on 14 Might after the corporate secured tentative approval from the US Meals and Drug Administration (USFDA) for its Abbreviated New Drug Utility (ANDA) for Darolutamide Tablets, 300 mg.
The approval marks one other vital step within the firm’s increasing presence within the oncology and specialty pharmaceutical segments in america. In keeping with the corporate’s regulatory submitting, the product is therapeutically equal to Bayer HealthCare Prescribed drugs’ prostate most cancers drug Nubeqa.
Darolutamide is an androgen receptor inhibitor prescribed for the remedy of superior prostate most cancers in grownup sufferers.
The medication is used for non-metastatic castration-resistant prostate most cancers (nmCRPC), metastatic castration-sensitive prostate most cancers (mCSPC), and together with docetaxel for sure mCSPC circumstances.
IQVIA estimates the US market alternative for the drug at almost $3.16 billion for the 12 months ending March 2026, highlighting the industrial significance of the approval.
Following the announcement, Alembic Pharma shares climbed shut to three% throughout intraday commerce earlier than trimming positive aspects later within the session. The inventory was buying and selling round Rs 778 in morning commerce, reflecting investor optimism across the firm’s regulated market pipeline.
The most recent improvement provides to Alembic’s rising listing of USFDA approvals. With the Darolutamide nod, the corporate has now secured a complete of 238 ANDA approvals from the US regulator, together with 219 last approvals and 19 tentative approvals.
Earlier, in April 2026, the corporate additionally acquired last approval from the USFDA for Fingolimod Capsules, 0.5 mg, a generic model of Novartis’ a number of sclerosis drug Gilenya. The medication targets relapsing types of a number of sclerosis and had an estimated US market dimension of $145 million. Alembic moreover expanded its worldwide footprint just lately by incorporating an entirely owned subsidiary in Germany to strengthen its European operations.
At 2:57 pm, the shares of Alembic Pharma had been buying and selling 2.72% increased at Rs 788.75 on NSE.
The way forward for investing is right here!
Tradz by EquityPandit leverages superior AI expertise to give you highly effective market predictions and actionable inventory scans. Obtain the app as we speakand 10x your buying and selling & investing journey!
